Ask AI

Turning Down the Heat in Hidradenitis Suppurativa: Translating Emerging Mechanistic Insights and Biologic Innovation Into Meaningful Patient Outcomes

Video
This activity is available for 1.00 CME/CE credit(s).

Released: September 08, 2026

Expiration: September 07, 2027

See Activity Collection

Understanding how to recognize hidradenitis suppurativa (HS) across diverse skin tones and phenotypes can shorten diagnostic delays and prevent irreversible tissue damage. Watch this on-demand webcast to learn about emerging mechanistic insights in HS, best practices for disease staging, and the latest data on biologic therapies, including how to translate these insights into practical treatment pathways to bring individualized care and shared decision-making strategies to patients with HS.

Emerging insights in hidradenitis suppurativa

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with hidradenitis suppurativa do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which of the following best describes your current role?

4.

A 29-yr-old Black woman has recurrent painful nodules in the axillae and groin for 10 yr. She has been repeatedly treated for furunculosis with incision and drainage and antibiotics. Examination shows inflammatory nodules and double-ended comedones.

Based on latest HS diagnostic criteria, which approach is most appropriate?

5.

A 38-yr-old Black woman with history of hypertension, PCOS, lupus, and Hurley stage II HS presents with nodules, abscesses, and tunnels that continue to drain despite topical and systemic antibiotics. She reports significant quality-of-life impairment, including pain and postinflammatory hyperpigmentation. Her dermatologist is considering escalation in therapy.

Which of the following would be the next best step in managing her disease?

6.

A 36-yr-old man visits doctor’s office for a follow-up. His HS progresses to Hurley stage III disease. He has failed treatment with adalimumab, isotretinoin, and infliximab. After reading about recently approved IL-17 inhibitors in an HS patient education brochure, he asks whether one of these newer treatment options could help better control his disease.

What would be the next best step for this patient to optimize control of his HS?